Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ROGOFF FAMILY TRUST DTD	2. Date of Event Requiring Statement (MM/DD/YYYY) 5/28/2021	3. Issuer Name and Ticker or Trading Symbol Immune Therapeutics, Inc. [IMUN]
(Last)        (First)        (Middle) 20701 N. SCOTTSDALE DR. STE. 107-501	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner _____ Officer (give title below)        ___X___ Other (specify below) / Member of 10% owner group
(Street) SCOTTSDALE, AZ 85255       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8266 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	2/13/2019	2/12/2024	Common Stock	20000	$5.00	D

Explanation of Responses:

(1)

According to the Annual Report on Form 10-K filed on April 15, 2021 (the "Form 10-K") by the issuer, Immune Therapeutics, Inc. (the "Company"), a reverse stock split of the Company's issued and outstanding, but not authorized, common stock at a ratio of 1,000-to-1 (the "Reverse Split") was approved by the Company's shareholders. The Reverse Split is currently pending approval by the Financial Industry Regulatory Authority, Inc. The information contained in the Form 10-K relating to the shares of Common Stock outstanding and beneficially owned is based on the implementation of the Reverse Split. The information presented herein is likewise based on the implementation of the Reverse Split. The beneficial ownership information presented in this Form 3 is otherwise based on the beneficial ownership of the Reporting Persons as of the date of the event requiring filing of this Form 3.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ROGOFF FAMILY TRUST DTD 20701 N. SCOTTSDALE DR. STE. 107-501 SCOTTSDALE, AZ 85255				Member of 10% owner group

Signatures
/s/ Rogoff Family Trust Dtd 5/10/1999; By Lawrence J. Rogoff, Trustee		5/28/2021
**Signature of Reporting Person		Date